Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors (EXCEL)
|Hypertension and Cardiovascular Risk Factors||Drug: CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)||Phase 4|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Real Life Experience With Caduet Evaluating Effectiveness, Safety and Tolerability in the Management of Cardiovascular Risk Factors (EXCEL Study)|
- Change in Systolic and Diastolic Blood Pressure [ Time Frame: Baseline, 24 weeks ]
|Study Start Date:||December 2007|
|Study Completion Date:||May 2008|
|Primary Completion Date:||May 2008 (Final data collection date for primary outcome measure)|
Drug: CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
Patients who have been prescribed single pill Caduet are eligible to participate in this study. The treating physician will obtain written informed consent from each subject or the subject's legally acceptable representative before any study-specific activity is performed.
The study terminated on May 5, 2008. The decision to terminate was due to inability to achieve study timelines and undue delay in obtaining IEC/IRB permission at some sites. No safety or efficacy issues caused the decision to terminate.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00579254
|Study Director:||Pfizer CT.gov Call Center||Pfizer|